An Open-Label, Single-Dose Study to Assess the Pharmacokinetics and Target Engagement in Cerebral Spinal Fluid and Plasma Following a Single Intravenous Dose of Fremanezumab 900 mg in Healthy Subjects First published 13/02/2023 Last updated 14/03/2024 EU PAS number:EUPAS103511 Study Ongoing